Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06680037
PHASE1

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Sponsor: TG Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).

Official title: A Phase 1, Open-label Study to Evaluate the Safety and Clinical Activity of Azercabtagene Zapreleucel in Participants With B-cell Mediated Autoimmune Disorders

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2025-05-06

Completion Date

2029-01-01

Last Updated

2026-04-07

Healthy Volunteers

No

Interventions

DRUG

Azercabtagene zapreleucel (azer-cel)

IV infusion

Locations (9)

TG Therapeutics Investigational Trial Site

La Jolla, California, United States

TG Therapeutics Investigational Trial Site

Lexington, Kentucky, United States

TG Therapeutics Investigational Trial Site

Ann Arbor, Michigan, United States

TG Therapeutics Investigational Trial Site

Omaha, Nebraska, United States

TG Therapeutics Investigational Trial Site

New York, New York, United States

TG Therapeutics Investigational Trial Site

Rochester, New York, United States

TG Therapeutics Investigational Trial Site

Cleveland, Ohio, United States

TG Therapeutics Investigational Trial Site

Columbus, Ohio, United States

TG Therapeutics Investigational Trial Site

Milwaukee, Wisconsin, United States